secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001193125-26-011872
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reiterates preliminary Q4 2025 PALSONIFY net product revenue over $5.0M
--------------------------------------------------------------------------------

- Net product revenue from PALSONIFY (paltusotine) exceeds $5.0M for Q4 2025.
- Audited FY2025 financials not yet available; estimates are preliminary and unaudited.
- CEO Scott Struthers presents company update at J.P. Morgan Healthcare Conference on Jan 13, 2026.
- Corporate slide presentation furnished as Exhibit 99.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312526011872/0001193125-26-011872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312526011872/d804277d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-011872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer